165 related articles for article (PubMed ID: 23906191)
1. The first approved agent in the Glitazar's Class: Saroglitazar.
Agrawal R
Curr Drug Targets; 2014 Feb; 15(2):151-5. PubMed ID: 23906191
[TBL] [Abstract][Full Text] [Related]
2. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
Krishnappa M; Patil K; Parmar K; Trivedi P; Mody N; Shah C; Faldu K; Maroo S; ; Parmar D
Cardiovasc Diabetol; 2020 Jun; 19(1):93. PubMed ID: 32560724
[TBL] [Abstract][Full Text] [Related]
3. Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.
Shetty SR; Kumar S; Mathur RP; Sharma KH; Jaiswal AD
Indian Heart J; 2015; 67(1):23-6. PubMed ID: 25820046
[TBL] [Abstract][Full Text] [Related]
4. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
Kaul U; Parmar D; Manjunath K; Shah M; Parmar K; Patil KP; Jaiswal A
Cardiovasc Diabetol; 2019 Jun; 18(1):80. PubMed ID: 31208414
[TBL] [Abstract][Full Text] [Related]
5. Saroglitazar for the treatment of dyslipidemia in diabetic patients.
Joshi SR
Expert Opin Pharmacother; 2015 Mar; 16(4):597-606. PubMed ID: 25674933
[TBL] [Abstract][Full Text] [Related]
6. Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.
Rastogi A; Dunbar RL; Thacker HP; Bhatt J; Parmar K; Parmar DV
Acta Diabetol; 2020 Jul; 57(7):809-818. PubMed ID: 32030508
[TBL] [Abstract][Full Text] [Related]
7. Virtual identification of novel PPARα/γ dual agonists by scaffold hopping of saroglitazar.
Jia WQ; Jing Z; Liu X; Feng XY; Liu YY; Wang SQ; Xu WR; Liu JW; Cheng XC
J Biomol Struct Dyn; 2018 Oct; 36(13):3496-3512. PubMed ID: 29081262
[TBL] [Abstract][Full Text] [Related]
8. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.
Goyal O; Nohria S; Goyal P; Kaur J; Sharma S; Sood A; Chhina RS
Sci Rep; 2020 Dec; 10(1):21117. PubMed ID: 33273703
[TBL] [Abstract][Full Text] [Related]
9. Study of Saroglitazar in Treatment Of Pre-diabetes with Dyslipidemia: STOP-D.
Bhosle D; Bhosle V; Bobde J; Bhagat A; Shaikh H; Kadam R
J Assoc Physicians India; 2018 Mar; 66(3):14-7. PubMed ID: 30341861
[TBL] [Abstract][Full Text] [Related]
10. A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia.
Balakumar P; Mahadevan N; Sambathkumar R
Curr Mol Pharmacol; 2019; 12(3):195-201. PubMed ID: 30636619
[TBL] [Abstract][Full Text] [Related]
11. A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy.
Deshpande A; Toshniwal H; Joshi S; Jani RH
PLoS One; 2016; 11(1):e0146222. PubMed ID: 26789842
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis.
Dutta D; Bhattacharya S; Surana V; Aggarwal S; Singla R; Khandelwal D; Sharma M
Diabetes Metab Syndr; 2020; 14(6):1759-1768. PubMed ID: 32937280
[TBL] [Abstract][Full Text] [Related]
13. The marketing of unproven drugs for diabetes and dyslipidaemia in India.
Luthra A; Misra A
Lancet Diabetes Endocrinol; 2015 Oct; 3(10):758-60. PubMed ID: 26386988
[No Abstract] [Full Text] [Related]
14. Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.
Patel MR; Kansagra KA; Parikh DP; Parmar DV; Patel HB; Soni MM; Patil US; Patel HV; Patel JA; Gujarathi SS; Parmar KV; Srinivas NR
Clin Drug Investig; 2018 Jan; 38(1):57-65. PubMed ID: 29022212
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders.
Patel H; Giri P; Patel P; Singh S; Gupta L; Patel U; Modi N; Shah K; Jain MR; Srinivas NR; Patel P
Xenobiotica; 2018 Dec; 48(12):1268-1277. PubMed ID: 29224415
[TBL] [Abstract][Full Text] [Related]
16. An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Mitra A
Cureus; 2020 Jul; 12(7):e9065. PubMed ID: 32782883
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.
Xu Y; Etgen GJ; Broderick CL; Canada E; Gonzalez I; Lamar J; Montrose-Rafizadeh C; Oldham BA; Osborne JJ; Xie C; Shi Q; Winneroski LL; York J; Yumibe N; Zink R; Mantlo N
J Med Chem; 2006 Sep; 49(19):5649-52. PubMed ID: 16970391
[TBL] [Abstract][Full Text] [Related]
18. Letter to the editor in response to the article 'Efficacy and safety of Saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis' (Dutta et al.).
Jaiswal A
Diabetes Metab Syndr; 2020; 14(6):2095. PubMed ID: 33147558
[No Abstract] [Full Text] [Related]
19. Saroglitazar Improves Transaminases and Elastography in Patients with Diabetic Dyslipidemia and Non-Alcoholic Fatty Liver Disease.
Goyal P; Goyal O; Chhina RS
J Assoc Physicians India; 2020 Jan; 68(1):97. PubMed ID: 31979903
[No Abstract] [Full Text] [Related]
20. Response to the letter to the editor submitted by Jaiswal A et al. (2020) regarding 'efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis' (Dutta et al.).
D D; S B; V S; S A; R S; D K; M S
Diabetes Metab Syndr; 2020; 14(6):2093. PubMed ID: 33147557
[No Abstract] [Full Text] [Related]
[Next] [New Search]
